Progress in neuro-psychopharmacology & biological psychiatry
January 10, 2025
Emma I Kopra, Jenni Penttinen, James J Rucker et al.
9 citations
Psychedelic drugs are increasingly visible in society once more, but their risks and adverse effects have received less attention than perhaps they should. While fatalities associated with psychedelics appear rare, a systematic approach to characterising their aetiology is required to inform harm minimisation efforts. This study aimed to analyse prevalence and characteristics of...
Neuropsychiatric Disease and Treatment
2024
Nadav Liam Modlin, Michael Creed, Maria Sarang et al.
18 citations
Post-traumatic stress disorder (PTSD) is associated with significant patient burden. While pharmacotherapies and evidence-based psychotherapy interventions (EBPI) are effective, studies consistently highlight inadequate outcomes and high treatment dropout. Psychedelic therapy (PT) has shown preliminary promise across difficult-to-treat conditions, including MDMA-assisted therapy for PTSD,...
Journal of Affective Disorders
April 1, 2023
Nadav Liam Modlin, Tammy M Miller, James J Rucker et al.
30 citations
Recent studies have demonstrated the promise of psilocybin therapies in creating positive changes for those with poor mental health across multiple diagnostic categories, including major depressive disorder (MDD), end-of-life anxiety, and obsessive-compulsive disorder (OCD). While there may be a large population that is eligible to participate in psilocybin therapy based on psychiatric...
Journal of Affective Disorders
February 1, 2023
Kwonmok Ko, Emma I Kopra, Anthony J. Cleare et al.
144 citations
Psychedelic therapy shows promise for Major Depressive Disorder, especially when treatment-resistant, as well as life-threatening illness distress. The objective of this systematic review, inclusive of meta-analysis, is to examine recent clinical research on the therapeutic effects of classic psychedelics on depressive symptoms. Fourteen psychedelic therapy studies, utilising psilocybin,...
Neuropsychiatric Disease and Treatment
2023
Kwonmok Ko, Ben Carter, Anthony J. Cleare et al.
26 citations
In psychedelic therapy, mystical as well as challenging experience may influence therapeutic outcome. However, predictors of such experience have not been sufficiently established. Determining predictors of their intensity is, therefore, potentially beneficial in targeting psilocybin therapy for depression. In a post hoc data analysis of a Phase 1, randomised, double-blind, placebo-controlled,...
Journal of Psychopharmacology
May 30, 2022
Chaitra Jairaj, James J Rucker
13 citations
Background: Postpartum depression (PPD) is a major public health concern and has, at its core, a sense of maternal ‘disconnection’ – from the self, the infant, and the support system. While PPD bears similarities with MDD, there is increasing evidence for its distinct nature, especially with the unique aspect of the mother-infant relationship. Current treatment modalities for PPD, largely based...
Expert Review of Neurotherapeutics
2022
Manaswini Pillai, Simon Erridge, Lara Bapir et al.
27 citations
The current paucity of clinical evidence limits the use of cannabis-based medicinal products (CBMPs) in post-traumatic stress disorder (PTSD). This study investigates health-related quality of life (HRQoL) changes and adverse events in patients prescribed CBMPs for PTSD. A case-series of patients from the UK Medical Cannabis Registry was analyzed. HRQoL was assessed at 1-, 3-, and 6-months...